Nxera Pharma to receive USD 8.6 million milestone payment from Centessa
CNTA•Milestone payment tied to OX2R agonist progress
- Nxera Pharma will receive a USD 8.6 million milestone payment from Centessa tied to late-stage development progress in its OX2R agonist portfolio.
- Revenue recognition is set for the third quarter of the fiscal year ending Dec. 31, 2026.
- Lilly completed its acquisition of Centessa on June 24, 2026, transferring ownership of the OX2R agonist pipeline.
- Nxera retains rights to future development milestones, commercialization milestones, and royalties linked to the programs.
